Guidelines in the management of diabetic nerve pain: Clinical utility of pregabalin

Diabetes, Metabolic Syndrome and Obesity

Volumn 6, Issue , 2013, Pages 57-78

  Vinik, Aaron I ^a   Casellini, Carolina M ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

Diabetes mellitus; Pain; Painful neuropathy; Pregabalin; Treatment

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPSAICIN; CLONIDINE; DEXTROMETHORPHAN; DULOXETINE; GABAPENTIN; HARKOSERIDE; LAMOTRIGINE; LIDOCAINE; MEXILETINE; MORPHINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NARCOTIC ANALGESIC AGENT; OXYCODONE; PLACEBO; PREGABALIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SODIUM CHANNEL BLOCKING AGENT; TAPENTADOL; THIOCTIC ACID; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE;

ALLODYNIA; ANOREXIA; ANXIETY; APPETITE; ATAXIA; BEDTIME DOSAGE; BLURRED VISION; BURNING SENSATION; CHRONIC PAIN; COMORBIDITY; CONFUSION; CONSTIPATION; CONTACT HEAT EVOKED POTENTIAL STIMULATION; DEPRESSION; DIABETIC NEUROPATHY; DIARRHEA; DISORDERS OF CARBOHYDRATE METABOLISM; DIZZINESS; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DYSESTHESIA; EDEMA; EPIDEMIOLOGICAL DATA; EVIDENCE BASED MEDICINE; FATIGUE; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; HOSPITAL COST; HUMAN; HYPERALGESIA; IMPAIRED FASTING GLUCOSE; IMPOTENCE; INTRAEPIDERMAL NERVE FIBER DENSITY; LABORATORY DIAGNOSIS; LATE LASER EVOKED POTENTIAL; LEUKOPENIA; LOCAL SKIN REACTION; LOW DRUG DOSE; NAUSEA; NERVOUS SYSTEM PARAMETERS; NEUROPATHIC PAIN; NOCICEPTIVE PAIN; NON INVASIVE PROCEDURE; NONHUMAN; ORTHOSTATIC HYPERTENSION; PAIN ASSESSMENT; PARESTHESIA; PERIPHERAL EDEMA; POSTHERPETIC NEURALGIA; PRACTICE GUIDELINE; QUALITY OF LIFE; REVIEW; SENSORIMOTOR NEUROPATHY; SIDE EFFECT; SINGLE DRUG DOSE; SKIN IRRITATION; SLEEP DISORDER; SMALL FIBER NEUROPATHY; SOMNOLENCE; SWEATING; TACHYCARDIA; TRANSCUTANEOUS NERVE STIMULATION; TREMOR; URINE RETENTION; WEIGHT GAIN; XEROSTOMIA;

EID: 84874399310     PISSN: 11787007     EISSN: None     Source Type: Journal    
DOI: 10.2147/DMSO.S24825     Document Type: Review

References (154)

1. Vinik A, Ullal J, Parson HK, Casellini CM. Diabetic neuropathies: clinical manifestations and current treatment options. Nat Clin Pract Endocrinol Metab. 2006;2:269-281.
2. Sadosky A, McDermott AM, Brandenburg NA, Strauss M. A review of the epidemiology of painful diabetic peripheral neuropathy, postherpetic neuralgia, and less commonly studied neuropathic pain conditions. Pain Pract. 2008;8:45-56.
3. Tesfaye S, Boulton AJ, Dyck PJ, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010;33:2285-2293.
4. Ziegler D. Painful diabetic neuropathy: treatment and future aspects. Diabetes Metab Res Rev. 2008;24 Suppl 1:S52-S57.
5. Boulton AJ, Malik RA, Arezzo JC, Sosenko JM. Diabetic somatic neuropathies. Diabetes Care. 2004;27:1458-1486.
6. Vinik AI, Ziegler D. Diabetic cardiovascular autonomic neuropathy. Circulation. 2007;115:387-397.
7. Vinik AI, Maser RE, Ziegler D. Neuropathy: the crystal ball for cardiovascular disease? Diabetes Care. 2010;33:1688-1690.
8. Vinik A, Maser R, Ziegler D. Autonomic imbalance: prophet of doom or scope for hope? Diabet Med. 2011;28:643-651.
9. Mantyselka P, Ahonen R, Kumpusalo E, Takala J. Variability in prescribing for musculoskeletal pain in Finnish primary health care. Pharm World Sci. 2001;23:232-236.
10. Treede RD, Jensen TS, Campbell JN, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology. 2008;70:1630-1635.
11. Jensen MP, Chodroff MJ, Dworkin RH. The impact of neuropathic pain on health-related quality of life: review and implications. Neurology. 2007;68:1178-1182.
12. Bouhassira D, Lanteri-Minet M, Attal N, Laurent B, Touboul C. Prevalence of chronic pain with neuropathic characteristics in the general population. Pain. 2008;136:380-387.
13. Vinik EJ, Hayes RP, Oglesby A, et al. The development and validation of the Norfolk QOL-DN, a new measure of patients' perception of the effects of diabetes and diabetic neuropathy. Diabetes Technol Ther. 2005;7:497-508.
14. Vinik E, Paulson J, Ford-Molvik S, Vinik A. German-translated Norfolk quality of life (QOL-DN) identifies the same factors as the English version of the tool and discriminates different levels of neuropathy severity. J Diabetes Sci Technol. 2008;2:1075-1086.
15. Bril V, England J, Franklin GM, et al. Evidence-based guideline: treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology. 2011;76:1758-1765.
16. Castro MM, Daltro C. Sleep patterns and symptoms of anxiety and depression in patients with chronic pain. Arq Neuropsiquiatr. 2009;67:25-28.
17. Gore M, Brandenburg NA, Dukes E, Hoffman DL, Tai KS, Stacey B. Pain severity in diabetic peripheral neuropathy is associated with patient functioning, symptom levels of anxiety and depression, and sleep. J Pain Symptom Manage. 2005;30:374-385.
18. Boulanger L, Zhao Y, Foster TS, Fraser K, Bledsoe SL, Russell MW. Impact of comorbid depression or anxiety on patterns of treatment and economic outcomes among patients with diabetic peripheral neuropathic pain. Curr Med Res Opin. 2009;25:1763-1773.
19. Gupta A, Silman J, Ray D, et al. The role of psychosocial factors in predicting the onset of chronic widespread pain: results from a prospective population-based study. Rheumatology (Oxford). 2007;46:666-671.
20. Vinik A, Zlateva G, Cheung R, Murphy K, Emir B, Whalen E. Understanding the impact of pain response on changes in function, quality of life, and sleep interference in patients with painful diabetic peripheral neuropathy and post-herpetic neuralgia treated with pregabalin. J Pain. 2010;11:S17.
21. O'Connor AB. Neuropathic pain: quality-of-life impact, costs and cost effectiveness of therapy. Pharmacoeconomics. 2009;27:95-112.
22. Van Acker K, Bouhassira D, De Bacquer D, et al. Prevalence and impact on quality of life of peripheral neuropathy with or without neuropathic pain in type 1 and type 2 diabetic patients attending hospital outpatients clinics. Diabetes Metab. 2009;35(3):206-213.
23. Daousi C, MacFarlane IA, Woodward A, Nurmikko TJ, Bundred PE, Benbow SJ. Chronic painful peripheral neuropathy in an urban community: a controlled comparison of people with and without diabetes. Diabet Med. 2004;21:976-982.
24. Krein SL, Heisler M, Piette JD, Makki F, Kerr EA. The effect of chronic pain on diabetes patients' self-management. Diabetes Care. 2005;28:65-70.
25. Zelman DC, Brandenburg NA, Gore M. Sleep impairment in patients with painful diabetic peripheral neuropathy. Clin J Pain. 2006;22:681-685.
26. Torrance N, Smith BH, Bennett MI, Lee AJ. The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. J Pain. 2006;7:281-289.
27. Dieleman JP, Kerklaan J, Huygen FJ, Bouma PA, Sturkenboom MC. Incidence rates and treatment of neuropathic pain conditions in the general population. Pain. 2008;137:681-688.
28. Cornblath DR, Vinik A, Feldman E, Freeman R, Boulton AJ. Surgical decompression for diabetic sensorimotor polyneuropathy. Diabetes Care. 2007;30:421-422.
29. Smith AG, Russell J, Feldman EL, et al. Lifestyle intervention for pre-diabetic neuropathy. Diabetes Care. 2006;29:1294-1299.
30. Ziegler D, Rathmann W, Meisinger C, Dickhaus T, Mielck A. Prevalence and risk factors of neuropathic pain in survivors of myocardial infarction with pre-diabetes and diabetes. The KORA Myocardial Infarction Registry. Eur J Pain. 2009;13:582-587.
31. Ziegler D, Rathmann W, Dickhaus T, Meisinger C, Mielck A. Neuropathic pain in diabetes, prediabetes and normal glucose tolerance: the MONICA/KORA Augsburg Surveys S2 and S3. Pain Med. 2009;10:393-400.
32. Pittenger G, Mehrabyan A, Simmons K, et al. Small fiber neuropathy is associated with the metabolic syndrome. Metab Syndr Relat Disord. 2005;3:113-121.
33. Tesfaye S, Chaturvedi N, Eaton SE, et al. Vascular risk factors and diabetic neuropathy. N Engl J Med. 2005;352:341-350.
34. Abbott CA, Malik RA, Van Ross ER, Kulkarni J, Boulton AJ. Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the UK. Diabetes Care. 2011;34:2220-2224.
35. Boulton AJ, Armstrong WD, Scarpello JH, Ward JD. The natural history of painful diabetic neuropathy -a 4-year study. Postgrad Med J. 1983;59:556-559.
36. Galer BS, Gianas A, Jensen MP. Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life. Diabetes Res Clin Pract. 2000;47:123-128.
37. Young RJ, Ewing DJ, Clarke BF. Chronic and remitting painful diabetic polyneuropathy. Correlations with clinical features and subsequent changes in neurophysiology. Diabetes Care. 1988;11:34-40.
38. Benbow SJ, Chan AW, Bowsher D, MacFarlane IA, Williams G. A pro-spective study of painful symptoms, small-fibre function and peripheral vascular disease in chronic painful diabetic neuropathy. Diabet Med. 1994;11:17-21.
39. Vinik AI, Strotmeyer ES, Nakave AA, Patel CV. Diabetic neuropathy in older adults. Clin Geriatr Med. 2008;24:407-435.
40. De Micheli A. Italian standards for diabetes mellitus 2007: executive summary: Diabete Italia, AMD Associazione Medici Diabetologi, SID Società Italiana di Diabetologia. Acta Diabetol. 2008;45: 107-127.
41. Bennett MI, Attal N, Backonja MM, et al. Using screening tools to identify neuropathic pain. Pain. 2007;127:199-203.
42. Bastyr E, Zhang D, Bril V, MBBQ Study Group. Neuropathy total symptom score-6 questionnaire (NTSS-6) is a valid instrument for assessing the positive symptoms of diabetic peripheral neuropathy (DPN). Diabetes. 2002;51:A199.
43. Scholz J, Mannion RJ, Hord DE, et al. A novel tool for the assessment of pain: validation in low back pain. PLoS Med. 2009;6:e1000047.
44. Spallone V. Painful Diabetic Neuropathy: Approach to diagnosis and treatment of an emergent problem. Me Dia. 2009;9:1-14.
45. Young RJ. Structural functional interactions in the natural history of diabetic polyneuropathy: a key to the understanding of neuropathic pain? Diabet Med. 1993;10 Suppl 2:89S-90S.
46. Feldman EL, Stevens MJ, Thomas PK, Brown MB, Canal N, Greene DA. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care. 1994;17:1281-1289.
47. Loeser JD, Treede RD. The Kyoto protocol of IASP Basic Pain Terminology. Pain. 2008;137:473-477.
48. Bouhassira D, Attal N, Fermanian J, et al. Development and validation of the Neuropathic Pain Symptom Inventory. Pain. 2004;108:248-257.
49. Bennett MI, Smith BH, Torrance N, Potter J. The S-LANSS score for identifying pain of predominantly neuropathic origin: validation for use in clinical and postal research. J Pain. 2005;6:149-158.
50. Krause S, Backonja M. Development of a neuropathic pain questionnaire. Clin J Pain. 2003;19:306-314.
51. Bouhassira D, Attal N, Alchaar H, et al. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain. 2005;114:29-36.
52. Freyhagen R, Baron R, Gockel U. Pain Detect: a new screening questionnaire to detect neuropathic components in patients with back pain. Curr Med Res Opin. 2006;22:1911-1920.
53. Portenoy R. Development and testing of a neuropathic pain screening questionnaire: ID Pain. Curr Med Res Opin. 2006;22:1555-1565.
54. Dworkin RH, Turk DC, Revicki DA, et al. Development and initial validation of an expanded and revised version of the Short-Form McGill Pain Questionnaire (SF-MPQ-2). Pain. 2009;144:35-42.
55. Daut RL, Cleeland CS, Flanery RC. Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. Pain. 1983;17:197-210.
56. Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain. 2008;9:105-121.
57. Cruccu G, Truini A. Tools for assessing neuropathic pain. PLoS Med. 2009;6:e1000045.
58. Lauria G, Hsieh S, Johansson O, et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neurol. 2010;17:903-912.
59. Stephenson DT, Arneric SP. Neuroimaging of pain: advances and future prospects. J Pain. 2008;9:567-579.
60. Chao CC, Hsieh SC, Tseng MT, Chang YC, Hsieh ST. Patterns of contact heat evoked potentials (CHEP) in neuropathy with skin denervation: correlation of CHEP amplitude with intraepidermal nerve fiber density. Clin Neurophysiol. 2008;119:653-661.
61. Atherton DD, Facer P, Roberts KM, et al. Use of the novel Contact Heat Evoked Potential Stimulator (CHEPS) for the assessment of small fibre neuropathy: correlations with skin flare responses and intra-epidermal nerve fibre counts. BMC Neurol. 2007;7:21.
62. Casanova-Molla J, Grau-Junyent JM, Morales M, Valls-Sole J. On the relationship between nociceptive evoked potentials and intraepidermal nerve fiber density in painful sensory polyneuropathies. Pain. 2011;152:410-418.
63. Chao CC, Tseng MT, Lin YJ, et al. Pathophysiology of neuropathic pain in type 2 diabetes: skin denervation and contact heat-evoked potentials. Diabetes Care. 2010;33:2654-2659.
64. Wong MC, Chung JW. Feasibility of contact heat evoked potentials for detection of diabetic neuropathy. Muscle Nerve. 2011;44:902-906.
65. Casellini CM, Vinik AI. Clinical manifestations and current treatment options for diabetic neuropathies. Endocr Pract. 2007;13:550-566.
66. Finnerup NB, Otto M, McQuay HJ, Jensen TS, Sindrup SH. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain. 2005;118:289-305.
67. Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. Pain. 2010;150:573-581.
68. Dworkin RH, O'Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain. 2007;132:237-251.
69. Dworkin RH, O'Connor AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc. 2010;85:S3-S14.
70. Vinik A. The approach to the management of the patient with neuropathic pain. J Clin Endocrinol Metab. 2010;95:4802-4811.
71. Edelsberg J, Oster G. Summary measures of number needed to treat: how much clinical guidance do they provide in neuropathic pain? Eur J Pain. 2009;13:11-16.
72. Tesfaye S, Vileikyte L, Rayman G, et al. Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management. Diabetes Metab Res Rev. 2011;27:629-638.
73. Said G, Bigo A, Ameri A, et al. Uncommon early-onset neuropathy in diabetic patients. J Neurol. 1998;245:61-68.
74. Dogrul A, Uzbay IT. Topical clonidine antinociception. Pain. 2004;111:385-391.
75. Ziegler D, Nowak H, Kempler P, Vargha P, Low PA. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabet Med. 2004;21:114-121.
76. Ziegler D, Ametov A, Barinov A, et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care. 2006;29:2365-2370.
77. Ziegler D, Low PA, Boulton AJM. Antioxidant treatment with alphalipoic acid in diabetic polyneuropathy: a 4-year randomized double-blind trial (NATHAN 1). Diabetologia. 2011;50:S63.
78. Ziegler D, Low PA, Litchy WJ, et al. Efficacy and safety of antioxidant treatment with alpha-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care. 2011;34:2054-2060.
79. Ziegler D. Thioctic acid for patients with symptomatic diabetic poly-neuropathy: a critical review. Treat Endocrinol. 2004;3:173-189.
80. Rains C, Bryson HM. Topical capsaicin. A review of its pharmacological properties and therapeutic potential in post-herpetic neuralgia, diabetic neuropathy and osteoarthritis. Drugs Aging. 1995;7:317-328.
81. Derry S, Lloyd R, Moore RA, McQuay HJ. Topical capsaicin for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2009;4:CD007393.
82. Mason L, Moore RA, Derry S, Edwards JE, McQuay HJ. Systematic review of topical capsaicin for the treatment of chronic pain. BMJ. 2004;328:991.
83. Backonja M, Wallace MS, Blonsky ER, et al. NGX-4010, a highconcentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study. Lancet Neurol. 2008;7:1106-1112.
84. Baron R, Mayoral V, Leijon G, Binder A, Steigerwald I, Serpell M. Efficacy and safety of combination therapy with 5% lidocaine medicated plaster and pregabalin in post-herpetic neuralgia and diabetic polyneuropathy. Curr Med Res Opin. 2009;25:1677-1687.
85. Jarvis B, Coukell AJ. Mexiletine. A review of its therapeutic use in painful diabetic neuropathy. Drugs. 1998;56:691-707.
86. Harati Y, Gooch C, Swenson M, et al. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology. 1998;50:1842-1846.
87. Harati Y, Gooch C, Swenson M, et al. Maintenance of the long-term effectiveness of tramadol in treatment of the pain of diabetic neuropathy. J Diabetes Complications. 2000;14:65-70.
88. Nelson KA, Park KM, Robinovitz E, Tsigos C, Max MB. High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia. Neurology. 1997;48:1212-1218.
89. Sang CN. NMDA-receptor antagonists in neuropathic pain: experimental methods to clinical trials. J Pain Symptom Manage. 2000;19:S21-S25.
90. Watson CP, Moulin D, Watt-Watson J, Gordon A, Eisenhoffer J. Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain. 2003; 105:71-78.
91. Gilron I, Bailey JM, Tu D, Holden RR, Weaver DF, Houlden RL. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med. 2005;352:1324-1334.
92. Schwartz S, Etropolski M, Shapiro DY, et al. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. Curr Med Res Opin. 2011;27:151-162.
93. Vinik A, Shapiro DY, Karcher K, Lange B, Rauschkolb C, Etropolski M. Patient global impression of change (PGIC) and brief pain inventory-short form (BPI-SF) assessments with tapentadol extended release (ER) for painful diabetic peripheral neuropathy (DPN). 72nd American Diabetes Association 72nd Scientific Sessions; June 8-12, 2012; Philadelphia, PA.
94. Schwartz S, Etropolski MS, Shapiro DY, et al. A pooled analysis evaluating efficacy and tolerability of tapentadol er for chronic, painful diabetic peripheral neuropathy (DPN). 72nd American Diabetes Association 72nd Scientific Sessions; June 8-12, 2012; Philadelphia, PA.
95. Max M, Lynch S, Muir J. Effects of desipramine, amitryptiline and fluoxetine on pain in diabetic neuropathy. N Engl J Med. 1992;326:1250-1256.
96. Kajdasz DK, Iyengar S, Desaiah D, et al. Duloxetine for the management of diabetic peripheral neuropathic pain: evidence-based findings from post hoc analysis of three multicenter, randomized, double-blind, placebo-controlled, parallel-group studies. Clin Ther. 2007; 29 Suppl:2536-2546.
97. Ziegler D, Pritchett YL, Wang F, et al. Impact of disease characteristics on the efficacy of duloxetine in diabetic peripheral neuropathic pain. Diabetes Care. 2007;30:664-669.
98. Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S. Duloxetine vs placebo in patients with painful diabetic neuropathy. Pain. 2005;116: 109-118.
99. Wernicke JF, Pritchett YL, D'Souza DN, et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology. 2006;67:1411-1420.
100. Hardy T, Sachson R, Shen S, Armbruster M, Boulton AJ. Does treatment with duloxetine for neuropathic pain impact glycemic control? Diabetes Care. 2007;30:21-26.
101. Sansone RA, Sansone LA. Pain, pain, go away: antidepressants and pain management. Psychiatry (Edgmont). 2008;5:16-19.
102. Simpson DA. Gabapentin and venlafaxine for the treatment of painful diabetic neuropathy. J Clin Neuromuscul Dis. 2001;3:53-62.
103. Rowbotham MC, Goli V, Kunz NR, Lei D. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain. 2004;110:697-706.
104. Blom S. Trigeminal neuralgia: its treatment with a new anticonvulsant drug (g-32883). Lancet. 1962;21:839-840.
105. LaRoche SM, Helmers SL. The new antiepileptic drugs: scientific review. JAMA. 2004;291:605-614.
106. Eisenberg E, Lurie Y, Braker C, Daoud D, Ishay A. Lamotrigine reduces painful diabetic neuropathy: a randomized, controlled study. Neurology. 2001;57:505-509.
107. Leach MJ, Marden CM, Miller AA. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: II. Neurochemical studies on the mechanism of action. Epilepsia. 1986;27: 490-497.
108. Coderre TJ, Melzack R. The contribution of excitatory amino acids to central sensitization and persistent nociception after formalin-induced tissue injury. J Neurosci. 1992;12:3665-3670.
109. Backonja MM. Use of anticonvulsants for treatment of neuropathic pain. Neurology. 2002;59:S14-S17.
110. Dworkin RH, Backonja M, Rowbotham MC, et al. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neurol. 2003;60:1524-1534.
111. Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA. 1998;280:1831-1836.
112. Landefeld CS, Steinman MA. The Neurontin legacy-marketing through misinformation and manipulation. N Engl J Med. 2009;360:103-106.
113. DeToledo JC, Toledo C, DeCerce J, Ramsay RE. Changes in body weight with chronic, high-dose gabapentin therapy. Ther Drug Monit. 1997;19:394-396.
114. Lesser H, Sharma U, LaMoreaux L, Poole RM. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology. 2004;63:2104-2110.
115. Richter RW, Portenoy R, Sharma U, LaMoreaux L, Bockbrader H, Knapp LE. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain. 2005;6:253-260.
116. Rosenstock J, Tuchman M, LaMoreaux L, Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain. 2004;110:628-638.
117. Freynhagen R, Strojek K, Griesing T, Whalen E, Balkenohl M. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible-and fixed-dose regimens. Pain. 2005;115:254-263.
118. Freeman R, Durso-Decruz E, Emir B. Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses. Diabetes Care. 2008;31:1448-1454.
119. Tolle T, Freynhagen R, Versavel M, Trostmann U, Young JJP. Pregabalin for relief of neuropathic pain associated with diabetic neuropathy: a randomized, double-blind study. Eur J Pain. 2008;12:203-213.
120. Arezzo JC, Rosenstock J, LaMoreaux L, Pauer L. Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: a double-blind placebo-controlled trial. BMC Neurol. 2008;8:33.
121. Sabatowski R, Galvez R, Cherry DA, et al. Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. Pain. 2004;109:26-35.
122. Dworkin RH, Corbin AE, Young JP Jr, et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology. 2003;60:1274-1283.
123. van Seventer R, Feister HA, Young JP Jr, Stoker M, Versavel M, Rigaudy L. Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: a 13-week, randomized trial. Curr Med Res Opin. 2006;22:375-84.
124. Kalso E. Sodium channel blockers in neuropathic pain. Curr Pharm Des. 2005;11:3005-3011.
125. Dogra S, Beydoun S, Mazzola J, Hopwood M, Wan Y. Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo-controlled study. Eur J Pain. 2005;9:543-554.
126. Vinik AI. Diabetic neuropathies: endpoints in clinical research studies. In: LeRoith D, Vinik AI, editors. Controversies in Treating Diabetes: Clinical and Research Aspects (Contemporary Endocrinology). Totowa, NJ: Humana Press; 2008:135-156.
127. Raskin P, Donofrio PD, Rosenthal NR, et al. Topiramate vs placebo in painful diabetic neuropathy: analgesic and metabolic effects. Neurology. 2004;63:865-873.
128. Donofrio PD, Raskin P, Rosenthal NR, et al. Safety and effectiveness of topiramate for the management of painful diabetic peripheral neuropathy in an open-label extension study. Clin Ther. 2005;27:1420-1431.
129. Boyd A, Barlow P, Pittenger G, Simmons K, Vinik A. Topiramate improves neurovascular function, epidermal nerve fiber morphology, and metabolism in patients with type 2 diabetes mellitus. Diabetes Metab Syndr Obes. 2010;2010:431-437.
130. Boyd A, Casellini C, Vinik E, Vinik A. Quality of life and objective measures of diabetic neuropathy in a prospective placebo-controlled trial of ruboxistaurin and topiramate. J Diabetes Sci Technol. 2011;5:714-722.
131. Quilici S, Chancellor J, Lothgren M, et al. Meta-analysis of duloxetine vs pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain. BMC Neurol. 2009;9:6-19.
132. Burke JP, Sanchez RJ, Joshi AV, Cappelleri JC, Kulakodlu M, Halpern R. Health care costs in patients with painful diabetic peripheral neuropathy prescribed pregabalin or duloxetine. Pain Pract. 2012;12:209-218.
133. de Salas-Cansado M, Perez C, Saldana MT, et al. An economic evaluation of pregabalin versus usual care in the management of community-treated patients with refractory painful diabetic peripheral neuropathy in primary care settings. Prim Care Diabetes. Epub May 15, 2012.
134. Bellows BK, Dahal A, Jiao T, Biskupiak J. A cost-utility analysis of pregabalin versus duloxetine for the treatment of painful diabetic neuropathy. J Pain Palliat Care Pharmacother. 2012;26:153-164.
135. Gilron I, Bailey JM, Tu D, Holden RR, Jackson AC, Houlden RL. Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial. Lancet. 2009;374:1252-1261.
136. Rief W. Lessons to be learned from placebo groups in clinical trials. Pain. 2011;152:1693-1694.
137. Tesfaye S, Tandan R, Bastyr EJ 3rd, Kles KA, Skljarevski V, Price KL. Factors that impact symptomatic diabetic peripheral neuropathy in placebo-administered patients from two 1-year clinical trials. Diabetes Care. 2007;30:2626-2632.
138. Häuser W, Bartram-Wunn E, Bartram C, Reinecke H, Tolle T. Systematic review: placebo response in drug trials of fibromyalgia syndrome and painful peripheral diabetic neuropathy-magnitude and patient-related predictors. Pain. 2011;152:1709-1717.
139. Obrosova I, Shevalye H. Metanx alleviates diabetes-induced large and small fiber neuropathies and promotes small sensory nerve fiber regeneration. Diabetes. 2011;60:652-P.
140. Fonseca VA, Lavery LA, Thethi TK, et al. A 24-week, double-blind, placebo controlled, multicenter study of Metanx in patients with diabetic peripheral neuropathy. Program and abstracts of the American Association of Clinical Endocrinologists 2011 Annual Meeting; April 13-17, 2011; San Diego, CA. Abstract 212.
141. Piovesan EJ, Teive HG, Kowacs PA, la Coletta MV, Werneck LC, Silberstein SD. An open study of botulinum-A toxin treatment of trigeminal neuralgia. Neurology. 2005;65:1306-1308.
142. Tsai CP, Liu CY, Lin KP, Wang KC. Efficacy of botulinum toxin type a in the relief of carpal tunnel syndrome: a preliminary experience. Clin Drug Investig. 2006;26:511-515.
143. Pittler MH, Ernst E. Complementary therapies for neuropathic and neuralgic pain: systematic review. Clin J Pain. 2008;24:731-733.
144. Tesfaye S. Painful diabetic neuropathy. Aetiology and nonpharmaco-logical treatment. In: Veves A, editor. Clinical Management of Diabetic Neuropathy. Totowa, NJ: Humana Press; 1998:369-386.
145. Abuaisha BB, Costanzi JB, Boulton AJ. Acupuncture for the treatment of chronic painful peripheral diabetic neuropathy: a long-term study. Diabetes Res Clin Pract. 1998;39:115-121.
146. Kumar D. Diabetic peripheral neuropathy: effectiveness of electro-therapy and amitriptyline for symptomatic relief. Diabetes Care. 1998;21:1322-1325.
147. Johnson MI, Bjordal JM. Transcutaneous electrical nerve stimulation for the management of painful conditions: focus on neuropathic pain. Expert Rev Neurother. 2011;11:735-753.
148. Claydon LS, Chesterton LS, Barlas P, Sim J. Dose-specific effects of transcutaneous electrical nerve stimulation (TENS) on experimental pain: a systematic review. Clin J Pain. 2011;27:635-647.
149. Moran F, Leonard T, Hawthorne S, et al. Hypoalgesia in response to transcutaneous electrical nerve stimulation (TENS) depends on stimulation intensity. J Pain. 2011;12:929-935.
150. Pantaleao MA, Laurino MF, Gallego NL, et al. Adjusting pulse amplitude during transcutaneous electrical nerve stimulation (TENS) application produces greater hypoalgesia. J Pain. 2011;12:581-590.
151. Tesfaye S, Watt J, Benbow SJ, Pang KA, Miles J, MacFarlane IA. Electrical spinal-cord stimulation for painful diabetic peripheral neuropathy. Lancet. 1996;348:1698-1701.
152. Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology, Chaudhry V, Stevens JC, Kincaid J, So YT. Practice Advisory: utility of surgical decompression for treatment of diabetic neuropathy: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2006;66:1805-1808.
153. Chaudhry V, Russell J, Belzberg A. Decompressive surgery of lower limbs for symmetrical diabetic peripheral neuropathy. Cochrane Database Syst Rev. 2008;16:CD006152.
154. Endotext.org [homepage on the internet]. Darmouth: Chapter 31-Diabetic Neuropathies; 2012 version [updated September 26, 2012]. Available from: http://www.endotext.org/diabetes/diabetes31/diabe-tesframe31.htm. Accessed December 12, 2012.